Our results identified that the dysregulated expression of CYP1B1 was associated with the clinical stage, tumor grade, immune cell infiltration, TMB, MSI, neoantigen, activation of multiple melatonergic and immune-related pathways, and therapeutic resistance. The gene discussed is CYP1B1; the disease is neoplasm.